---
document_datetime: 2025-06-10 13:37:58
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vokanamet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vokanamet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0203593
conversion_datetime: 2025-12-26 20:44:26.107755
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vokanamet

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.3 Change(s) in the Summary of Product | 10/06/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000261685                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority - Accepted C.I.3.z (Type IB) - To update section 4.4 of the SmPC to implement the signal recommendations from PSUR outcome for the metformin PSUSA/00002001/202404. Section 2 of the Package Leaflet was updated accordingly. In addition, a typo has been correct in the Icelandic local representative in section 6 of the Package   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000249050 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted   |
|--------------------------------------------------------------------------------------------------------------------|